Shortening The Timeline From Customer Into Clinics: Development Of A Downstream Processing Platform For Adeno-Associated Virus (AAV)

By Jule Greschok and Mathias Kahl, Process Development, IDT Biologika, Magdeburg, and Dr. Thomas Kreisig, Analytical Development, IDT Biologika, Dessau

Many diseases are caused by gene defects and often have little to no treatment options. Gene therapies based on viral vectors offer the possibility of minimizing or completely eliminating the symptoms of the gene defect. However, gene therapies come at a high cost to patients and are not yet widely accessible to those in need of life-saving treatment. There is a growing need for manufacturers to provide innovative development and manufacturing solutions to reduce costs while maintaining high product quality and safety.

IDT Biologika has developed a purification platform for Adeno-Associated Virus (AAV) based on sophisticated experimental data and a multi-criteria decision matrix. This intense study revealed valuable insights into AAV-specific challenges and enabled the well-informed selection of the most suitable purification technologies and strategy, helping to reduce production costs while ensuring reliability.

This poster presents investigations to derive an economic and scalable method for purification of AAV.